Editorial

All that wheezes…

Aparna Bhat, MD and Rendell W. Ashton, MD
Cleveland Clinic Journal of Medicine March 2021, 88 (3) 150-153; DOI: https://doi.org/10.3949/ccjm.88a.20198

Article Figures & Data

Figures

Tables

  • TABLE 1

    Global Initiative for Chronic Obstructive Lung Disease classification of COPD, with recommended therapy

    ExacerbationsmMRC 0–1; CAT < 10mMRC ≥ 2; CAT ≥ 10
    0 or 1 moderate exacerbation in the past year (not leading to hospital admission)Group A
    Short- or long-acting bronchodilator    		Group B
    LABA
    or LAMA
    ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization within the past yearGroup C
    LAMA    		Group D
    LAMA
    or LAMA + LABA
    or inhaled corticosteroid + LABA

    • CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; LABA = long-acting beta-2 agonist; LAMA = long-acting muscarinic receptor antagonist; mMRC = Modified Medical Research Council dyspnea questionnaire

    • Adapted from Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019. Accessed February 10, 2021. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects